Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.
Amado J. Zurita-Saavedra, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer (HSPC).
Ongoing clinical trials are evaluating PARP inhibitors, AKT inhibitors, and lutetium 177 (177Lu)–PSMA-617 as frontline therapies for men with metastatic HSPC, Zurita-Saavedra explains. Some emerging therapies may have utility in all-comers, whereas others will be reserved for molecularly defined subsets of patients.
Moreover, based on the data that emerged with antiandrogen agents like enzalutamide (Xtandi) and apalutamide (Erleada), it is likely that emerging agents will be combined with these agents to further improve outcomes for patients with metastatic HSPC, Zurita-Saavedra concludes.